Safety and Efficacy Study of Besivance™ for Treatment of Congenital Nasolacrimal Duct Obstruction in Children
Conditions
- Congenital Nasolacrimal Duct Obstruction
Interventions
- DRUG: Besivance Treatment Group
- DRUG: Polytrim Treatment Group
Sponsor
Rutgers, The State University of New Jersey
Collaborators